BioNTech (NASDAQ:BNTX) Shares Gap Down – Here’s Why

Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) gapped down prior to trading on Thursday . The stock had previously closed at $111.70, but opened at $105.50. BioNTech shares last traded at $105.97, with a volume of 447,244 shares trading hands.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. JPMorgan Chase & Co. decreased their price target on shares of BioNTech from $121.00 to $120.00 and set a “neutral” rating on the stock in a research note on Thursday, October 23rd. Wells Fargo & Company set a $150.00 target price on shares of BioNTech and gave the stock an “overweight” rating in a research note on Tuesday, August 5th. UBS Group increased their price target on BioNTech from $115.00 to $117.00 and gave the stock a “neutral” rating in a research note on Thursday, November 6th. Bank of America lowered their price objective on BioNTech from $134.00 to $130.00 and set a “buy” rating for the company in a research report on Wednesday, October 22nd. Finally, HC Wainwright lifted their price target on BioNTech from $136.00 to $140.00 and gave the company a “buy” rating in a report on Monday. Eleven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, BioNTech currently has a consensus rating of “Moderate Buy” and a consensus target price of $134.10.

BioNTech Stock Down 6.5%

The firm’s fifty day moving average is $103.09 and its 200-day moving average is $104.95. The stock has a market capitalization of $25.11 billion, a price-to-earnings ratio of -65.85 and a beta of 1.54. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.61 and a quick ratio of 8.48.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Monday, November 3rd. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of $0.75 by ($0.89). The firm had revenue of $1.78 billion during the quarter, compared to the consensus estimate of $1.21 billion. BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The firm’s quarterly revenue was up 22.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.81 earnings per share. BioNTech has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current year.

Institutional Trading of BioNTech

Several hedge funds have recently made changes to their positions in the stock. Financial Consulate Inc. acquired a new position in BioNTech during the 3rd quarter valued at approximately $36,000. Banque Cantonale Vaudoise acquired a new stake in BioNTech in the first quarter worth $36,000. Huntington National Bank lifted its stake in BioNTech by 1,266.7% in the third quarter. Huntington National Bank now owns 410 shares of the company’s stock valued at $40,000 after buying an additional 380 shares during the last quarter. LRI Investments LLC grew its position in shares of BioNTech by 234.6% during the second quarter. LRI Investments LLC now owns 445 shares of the company’s stock worth $47,000 after acquiring an additional 312 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in shares of BioNTech by 118.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock worth $60,000 after acquiring an additional 305 shares during the period. Institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.